We are thrilled to announce the launch of Myhibbin, the new FDA-approved liquid form of the immunosuppressant mycophenolate mofetil, expertly renamed by WANT Branding! Azurity Pharmaceuticals hired WANT to develop this innovative name, resulting in the clever fusion of “Mycophenolate” and “Inhibit.” The name Myhibbin not only reflects its active ingredient but also its critical function in inhibiting the immune response to prevent organ rejection. Designed for kidney, heart, and liver transplant recipients aged three months and older, Myhibbin, when used in combination with other immunosuppressants, promises to enhance the lives of transplant patients by offering a powerful and effective solution. With Myhibbin, we’re taking a significant step forward in transplant care, ensuring patients receive the best possible protection for their precious new organs.